April 16, 2012 | last updated June 1, 2012 1:54 pm

CT's Rib-X names Wikler its development chief

New Haven antibiotics developer Rib-X Pharmaceuticals hired a former senior federal drug regulator and an expert on infectious disease to shepherd its delafloxacin treatment through screening on its way to market.

Matthew A. Wikler, M.D., becomes Rib-X's chief development officer, effective April 30.

Wikler is a former deputy director of the Food and Drug Administration, which must clear Rib-X's delafloxacin, which finished Phase 2b clinical testing for acute bacterial skin and skin structure infections last December.

The drug will soon begin Phase 3 trials, authorities said.

Wikler most recently was CEO of IASO Pharma Inc., a San Diego biopharma startup also developing antibacterial and antifungal therapeutics. He also worked at several established drug and health-products firms.

Wikler's BA is from Franklin and Marshall College, his medical degree is from Temple University, and MBA from the University of Pennsylvania's Wharton School of Business.

Comments

Type your comment here:

Today's Poll
ADVERTISEMENTS
Most Popular on Facebook
Copyright 2014 New England Business Media